Comparison of Contemporary Radiation Therapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331

Hoppe BS, Mailhot-Vega RB, Renfro LA, Pei Q, Charpentier AM, Parikh RR, Roberts KB, Keller FG, Punnett A, Parsons S, Voss SD, Alzaraki A, McCarten KM, Flampouri S, Kessel S, Wu Y, Cho SY, Kelly KM, Castellino SM, Hodgson DC. Comparison of Contemporary Radiation Therapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331. Int J Radiat Oncol Biol Phys. 2025 Jun 28:S0360-3016(25)04518-3. doi: 10.1016/j.ijrobp.2025.06.3876. Epub ahead of print. PMID: 40588069; PMCID: PMC12308618.

AHOD 1331 was a clinical trial investigating brentuximab vedotin in conjunction with chemotherapy and response adapted radiation therapy (RT) in pediatric patients with high-risk classic Hodgkin lymphoma. RT was delivered using 3-dimensional conformal RT (3D-CRT), intensity modulated RT (IMRT), or proton therapy. This analysis evaluated dosimetric and clinical outcomes for patients treated across these different RT modalities.